Opposing regulatory roles of complement factor 5 in the development of bleomycin-induced pulmonary fibrosis

Journal of Immunology

Volumn 175, Issue 3, 2005, Pages 1894-1902

  Addis Lieser, Erin ^a   Köhl, Jörg ^a   Chiaramonte, Mónica G ^a,b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5A; CYTOKINE; MATRIX METALLOPROTEINASE; STROMELYSIN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; COMPLEMENT SYSTEM; CONTROLLED STUDY; FIBROBLAST; IDIOPATHIC DISEASE; IMMUNE RESPONSE; INFLAMMATORY DISEASE; INTERSTITIAL LUNG DISEASE; LUNG FIBROSIS; MEDIATOR; MOUSE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE REPAIR;

EID: 22544452680     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.3.1894     Document Type: Article

References (71)

1. American Thoracic Society. 2000. Idiopathic pulmonary fibrosis: diagnosis and treatment: International consensus statement: American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am. J. Respir. Crit. Care Med. 161: 646-661.
2. Coultas, D. B., and M. P. Hughes. 1996. Accuracy of mortality data for interstitial lung diseases in New Mexico, USA. Thorax 51: 717-720.
3. Zhang, Y., T. C. Lee, B. Guillemin, M. C. Yu, and W. N. Rom. 1993. Enhanced IL-1β and tumor necrosis factor-α release and messenger RNA expression in macrophages from idiopathic pulmonary fibrosis or after asbestos exposure. J. Immunol. 150: 4188-4196.
4. Ziegenhagen, M. W., S. Schrum, G. Zissel, P. F. Zipfel, M. Schlaak, and J. Muller-Quemheim. 1998. Increased expression of proinflammatory chemokines in bronchoalveolar lavage cells of patients with progressing idiopathic pulmonary fibrosis and sarcoidosis. J. Invest. Med. 46: 223-231.
5. Martinet, Y., O. Menard, P. Vaillant, J. M. Vignaud, and N. Martinet. 1996. Cytokines in human lung fibrosis. Arch. Toxicol. Suppl. 18: 127-139.
6. Richeldi, L., H. R. Davies, G. Ferrara, and F. Franco. 2003. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst. Rev. 3:CD002880.
7. Bowden, D. H. 1984. Unraveling pulmonary fibrosis: the bleomycin model. Lab. Invest. 50: 487-488.
8. Riedemann, N. C., R. F. Guo, T. A. Neff, I. J. Laudes, K. A. Keller, V. J. Sarma. M. M. Markiewski, D. Mastellos, C. W. Stay, C. L. Pierson, et al. 2002. Increased C5a receptor expression in sepsis. J. Clin. Invest. 110: 101-108.
9. Kohl, J., and J. E. Gessner. 1999. On the role of complement and Fcy-receptors in the Arthus reaction. Mol. Immunol. 36: 893-903.
10. Karp, C. L., and M. Wills-Karp. 2001. Complement and IL-12: yin and yang. Microbes Infect. 3: 109-119.
11. Drouin, S. M., J. Kildsgaard, J. Haviland, J. Zabner, H. P. Jia, P. B. McCray, Jr., B. F. Tack, and R. A. Wetsel. 2001. Expression of the complement anaphylatoxin C3a and C5a receptors on bronchial epithelial and smooth muscle cells in models of sepsis and asthma. J. Immunol. 166: 2025-2032.
12. Hugli, T. E. 1986. Biochemistry and biology of anaphylatoxins. Complement 3: 111-127.
13. Lett-Brown, M. A., and E. J. Leonard 1977. Histamine-induced inhibition of normal human basophil chemotaxis to C5a. J. Immunol. 118; 815-818.
14. Schmid, E., R. L. Wamer, L. D. Crouch, H. P. Friedl, G. O. Till, T. E. Hugli, and P. A. Ward. 1997. Neutrophil chemotactic activity and C5a following systemic, activation of complement in rats. Inflammation 21: 325-333.
15. Richards, S. W., P. K. Peterson, H. A. Verbrugh, R. D. Nelson, D. E. Hammerschmidt, and J. R, Hoidal. 1984. Chemotactic and phagocytic responses of human alveolar macrophages to activated complement components. Infect. Immun. 43: 775-778.
16. Ottonello, L., A. Corcione, G. Tortolina, I. Airoldi, E. Albesiano, A. Favre, R. D'Agostino, F. Malavasi, V. Pistoia, and F. Dallegri. 1999. rC5a directs the in vitro migration of human memory and naive tonsillar B lymphocytes: implications for B cell trafficking in secondary lymphoid tissues. J. Immunol. 162: 6510-6517.
17. Werfel, T., M. Oppermann, J. H. Butteifield, G. Begemann, J. Eisner, O. Gotze, and J. Zwimer. 1996. The human mast cell line HMC-1 expresses C5a receptors and responds to C5a but not to CSa(desArg). Scand. J. Immunol. 44: 30-36.
18. Mastellos, D., and J. D. Lambris. 2002. Complement: more than a 'guard' against invading pathogens? Trends Immunol. 23: 485-491.
19. Cole, D. S., and B. P. Morgan. 2003. Beyond lysis: how complement influences cell fate. Clin. Sci. 104: 455-466.
20. Dreisin, R. B., M. I. Schwarz, A. N. Theofilopoulos, and R. E. Stanford. 1978. Circulating immune complexes in the idiopathic interstitial pneumonias. N. Engl. J. Med. 298: 353-357.
21. Haslam, P. L., F. Allan, A. F. Watling, C. Barrett, L. Morris, and M. Turner-Warwick. 1982. Impaired antibody-dependent cell-mediated cytotoxicity in cryptogenic fibrosing alveolitis (synonym: idiopathic pulmonary fibrosis). Clin. Exp. Immunol. 49: 59-66.
22. Jansen, H. M., A. J. Schutte, J. D. Elema, M. V. Giessen, R. P. Reig, M. A. Leeuwen, H. J. Sluiter, and T. H. The. 1984. Local immune complexes and inflammatory response in patients with chronic interstitial pulmonary disorders associated with collagen vascular diseases. Clin. Exp. Immunol. 56: 311-320.
23. Phan, S. H., and R. S. Thrall. 1982. Inhibition of bleomycin-induced pulmonary fibrosis by cobra venom factor. Am. J. Pathol. 107: 25-28.
24. Wheat, W. H., R. Wetsel, A. Falus, B. F. Tack, and R. C. Strunk. 1987. The fifth component of complement (C5) in the mouse: analysis of the molecular basis for deficiency. J. Exp. Med. 165: 1442-1417.
25. Chen, E. S., B. M. Greenlee, M. Wills-Karp, and D. R. Moller. 2001. Attenuation of lung inflammation and fibrosis in interferon-7-deficient mice after intratracheal bleomycin. Am. J. Respir. Cell Mol. Biol. 24: 545-555.
26. Wang, Y., S. A. Rollins, J. A. Madri, and L. A. Matis. 1995. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc. Natl. Acad. Sci. USA 92: 8955-8959.
27. Frei, Y., J. D. Lambris, and B. Stockinger. 1987. Generation of a monoclonal antibody to mouse C5 application in an ELISA assay for detection of anti-C5 antibodies. Mol. Cell Probes 1: 141-149.
28. Chiaramonte, M. G., M. Mentink-Kane, B. A. Jacobson, A. W. Cheever, M. J. Whitters, M. E. Goad, A. Wong, M. Collins, D. D. Donaldson, M. J. Grusby, and T. A. Wynn. 2003. Regulation and function of the interleukin 13 receptor α2 during a T helper cell type 2-dominant immune response. J. Exp. Med. 197: 687-701.
29. Boutin, H., R. A. LeFeuvre, R. Horai, M. Asano, Y. Iwakura, and N. J. Rothwell. 2001. Role of IL-1α and IL-1β in ischemic brain damage. J. Neurosci. 21: 5528-5534.
30. Overbergh, L., D. Valckx, M. Waer, and C. Mathieu. 1999. Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptase PCR. Cytokine 11: 305-312.
31. Vaillant, B., M. G. Chiaramonte, A. W. Cheever, P, D. Soloway, and T. A. Wynn. 2001. Regulation of hepatic fibrosis and extracellular matrix genes by the Th response: new insight into the role of tissue inhibitors of matrix metalloproteinases. J. Immunol. 167: 7017-7026.
32. Bergman, I., and R. Loxley. 1963. Two improved and simplified methods for the spectrophotometric determination of hydroxyproline. Anal. Biochem. 35: 1961-1965.
33. Zwirner, J., A. Fayyazi, and O. Gotze. 1999. Expression of the anaphylatoxin C5a receptor in non-myeloid cells. Mol. Immunol. 36: 877-884.
34. Barton, P. A., and J. S. Warren. 1993. Complement component C5 modulates the systemic tumor necrosis factor response in murine endotoxic shock. Infect. Immun. 61: 1474-1481.
35. Mastellos, D., J. C. Papadimitriou, S. Franchira, P. A. Tsonis, and J. D. Lambris. 2001. A novel role of complement: mice deficient in the fifth component of complement (C5) exhibit impaired liver regeneration. J. Immunol. 166: 2479-2486.
36. Wang, Q., Y. Wang, D. M. Hyde, P. J. Gotwals, V. E. Koteliansky, S. T. Ryan, and S. N. Giri. 1999. Reduction of bleomycin induced lung fibrosis by transforming growth factor β soluble receptor in hamsters. Thorax 54: 805-812.
37. Letterio, J. J., and A. B. Roberts. 1998. Regulation of immune responses by TGF-β. Annu. Rev. Immunol. 16: 137-161.
38. Parks, W. C., C. L. Wilson, and Y. S. Lopez-Boado. 2004. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat. Rev. Immunol. 4: 617-629.
39. Parks, W. C., and S. D. Shapiro. 2001. Matrix metalloproteinases in lung biology. Respir. Res. 2: 10-19.
40. Gomez, D. E., D. F. Alonso, H. Yoshiji, and U. P. Thorgeirsson. 1997. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur. J. Cell Biol. 74: 111-122.
41. Suzuki, R., Y, Miyazaki, K. Takagi, K. Torii, and H. Taniguchi. 2004. Matrix metalloproteinases in the pathogenesis of asthma and COPD: implications for therapy. Treat. Respir. Med. 3: 17-27.
42. Bullard, K. M., L. Lund, J. S. Mudgett, T. N. Mellin, T. K. Hunt, B. Murphy, J. Ronan, Z. Werb, and M. J. Banda. 1999. Impaired wound contraction in stromelysin-1-deficient mice. Ann. Surg. 230: 260-265.
43. Unemori, E. N., M. J. Bair, E. A. Bauer, and E. P. Amento. 1991. Stromelysin expression regulates collagenase activation in human fibroblasts: dissociable control of two metalloproteinases by interferon-γ. J. Biol. Chem. 266: 23477-23482.
44. Pilcher, B. K., M. Wang, X. J. Qin, W. C. Parks, R. M. Senior, and H. G. Welgus. 1999. Role of matrix metalloproteinases and their inhibition in cutaneous wound healing and allergic contact hypersensitivity. Ann. NY Acad. Sci. 878: 12-24.
45. Bullard, K. M., J. Mudgett, H. Scheuenstuhl, T. K. Hunt, and M. J. Banda. 1999. Stromelysin-1-deficient fibroblasts display impaired contraction in vitro. J. Surg. Res. 84: 31-34.
46. Gerald, C., and N. P. Gerard. 1994. C5a anaphylatoxin and its seven transmembrane-segment receptor. Annu. Rev. Immunol. 12: 775-808.
47. Suga, M., K. Iyonaga, T. Okamoto, Y. Gushima, H. Miyakawa, T. Akaike, and M. Ando, 2000. Characteristic elevation of matrix metalloproteinase activity in idiopamic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 162: 1949-1956.
48. Selman, M., V. Ruiz, S. Cabrera, L. Segura, R. Ramirez, R. Barrios, and A. Pardo. 2000. TIMP-1, -2, -3, and -4 in idiopathic pulmonary fibrosis: a prevailing nondegradative lung microenvironment? Am. J. Physiol. Lung Cell Mol. Physiol. 279: L562-L574.
49. Swiderski, R. E., J. E. Dencoff, C. S. Floerchinger, S. D. Shapiro, and G. W. Hunninghake. 1998. Differential expression of extracellular matrix remodeling genes in a murine model of bleomycin-induced pulmonary fibrosis. Am. J. Pathol. 152: 821-828.
50. Corbel, M., C. Belleguic, E. Boichot, and V. Lagente. 2002. Involvement of gelatinases (MMP-2 and MMP-9) in the development of airway inflammation and pulmonary fibrosis. Cell Biol. Toxicol. 18: 51-61.
51. Werb, Z., and J. R. Chin. 1998. Extracellular matrix remodeling during morphogenesis. Ann. NY Acad. Sci. 857: 110-118.
52. Van Den Steen, P. E.. A. Wuyts, S. J. Husson, P. Proost, J. Van Damme, and G. Opdenakker. 2003. Gelatinase B/MMP-9 and neutrophil collagenase/MMP-8 process the chemokines human GCP-2/CXCL6, ENA-78/CXCL5 and mouse GCP-2/LIX and modulate their physiological activities. Eur. J. Biochem. 270: 3739-3749.
53. Sitia, G., M, Isogawa, M. Iannacone, I. L. Campbell, F. V. Chisari, and L. G. Guidotti. 2004. MMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLs. J. Clin. Invest. 113: 1158-1167.
54. Shipley, J. M., R. L. Wesselschmidt, D. K. Kobayashi, T. J. Ley, and S. D. Shapiro. 1996. Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc. Natl. Acad. Sci. USA 93: 3942-3946.
55. Warner, R. L., L. Beltran, E. M. Younkin, C. S. Lewis, S. J. Weiss, J. Varani, and K. J. Johnson. 2001. Role of stromelysin 1 and gelatinase B in experimental acute lung injury. Am. J. Respir. Cell Mol. Biol. 24: 537-544.
56. Lee, K. S., S. M. Jin, H. J. Kim, and Y. C. Lee. 2003. Matrix metalloproteinase inhibitor regulates inflammatory cell migration by reducing 1CAM-1 and VCAM-1 expression in a murine model of toluene diisocyanate-induced asthma. J. Allergy Clin. Immunol. 111: 1278-1284.
57. Betsuyaku, T., Y. Fukuda, W. C. Parks, J. M. Shipley, and R. M. Senior. 2000. Gelatinase B is required for alveolar bronchiolization after intratracheal bleomycin. Am. J. Pathol. 157: 525-535.
58. Bhatia, M., A. K. Saluja, V. P. Singh, J. L. Frossard, H. S. Lee, L. Bhagat, C. Gerard, and M. L. Steer. 2001. Complement factor C5a exerts an antiinflammatory effect in acute pancreatitis and associated lung injury. Am. J. Physiol. Gastrointest. Liver Physiol. 280: G974-G978.
59. Osaka, H., P. Mukherjee, P. S. Aisen, and G. M. Pasinetti. 1999. Complement-derived anaphylatoxin C5a protects against glutamate-mediated neurotoxicity. J. Cell. Biochem. 73: 303-311.
60. Foxman, E. F., J. J. Campbell, and E. C. Butcher. 1997. Multistep navigation and the combinatorial control of leukocyte chemotaxis. J. Cell Biol. 139: 1349-1360.
61. Broekelmann, T. J., A. H. Limper, T. V. Colby, and J. A. McDonald. 1991. Transforming growth factor β1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc. Natl. Acad. Sci. USA 88: 6642-6646.
62. Henry, M. T., K. McMahon, A. J. Mackarel, K. Prikk, T. Sorsa, P. Maisi, R. Sepper, M. X. Fitzgerald, and C. M. O'Connor. 2002. Matrix metalloproteinases and tissue inhibitor of metalloproteinase-1 in sarcoidosis and IPF. Eur. Respir. J. 20: 1220-1227.
63. Welgus, H. G. 1991. Stromeiysin: structure and function. Agents Actions Suppl. 35: 61-67.
64. Massarotti, M., B. Marasini, A. Marchesoni, M. Arreghini, and M. L. Biondi. 2003. Polymorphism in the stromelysin 1 (matrix metalloproteinase 3) promoter gene and severity of rheumatoid arthritis: comment on the article by Constantin et al. Arthritis Rheum. 48: 2695-2696.
65. Tchetverikov, I., L. R. Lard, J. DeGroot, N. Verzijl, J. M. TeKoppele, F. C. Breedveld, T. W, Huizinga, and R. Hanemaaijer. 2003. Matrix metalloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis. Ann. Rheum. Dis. 62: 1094-1099.
66. Humphries, S. E., S. Martin, J. Cooper, and G. Miller. 2002. Interaction between smoking and the stromelysin-1 (MMP3) gene 5A/6A promoter polymorphism and risk of coronary heart disease in healthy men, Ann. Hum. Genet. 66: 343-352.
67. Fireman, E., I. Shahar, S. Shoval, G. Messer, S. Dvash, and J. Grief. 2001. Morphological and biochemical properties of alveolar fibroblasts in interstitial lung diseases. Lung 179: 105-117.
68. Huaux, F., T. Liu, B. McGarry, M. Ullenbruch, and S. H. Phan. 2003. Dual roles of IL-4 in lung injury and fibrosis. J. Immunol. 170: 2083-2092.
69. Sheppard, D. 2001. Integrin-mediated activation of transforming growth factor-β(1) in pulmonary fibrosis. Chest 120: 49S-53S.
70. Hillmen, P., C. Hall, J. C. Marsh, M. Elebute, M. P. Bombara, B. E. Petro, M. J. Cullen, S. J. Richards, S. A. Rollins, C. F. Mojcik, and R. P. Rother. 2004. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 350: 552-559.
71. Otto, M., H. Hawlisch, P. N. Monk, M. Muller, A. Klos, C. L. Karp, and J. Kohl. 2004. C5a mutants are potent antagonists of the C5a receptor (CD88) and of C5L2: position 69 is the locus that determines agonism or antagonism. J. Biol. Chem. 279: 142-151.